anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Nuvalent · pitchdeck

Nuvalent | IPO Presentation Deck | 40 slides

40 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Nuvalent | IPO Presentation Deck | 40 slides

Nuvalent · 2021-07
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 7 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits
— 0/2 slides
— 0/2 slides
100% 2/2 slides 100% 2/2 slides
— 0/2 slides
Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Market Sizing 2 slides 100% 2/2 slides 100% 2/2 slides · 8 hits
— 0/2 slides
100% 2/2 slides 100% 2/2 slides 100% 2/2 slides · 3 hits
— 0/2 slides
Competition 2 slides 100% 2/2 slides 100% 2/2 slides · 9 hits
— 0/2 slides
50% 1/2 slides 50% 1/2 slides 100% 2/2 slides · 3 hits
— 0/2 slides

Slide inventory

40
every slide · same image gating as the playbook
01
Slide 1
Features a molecular structure visualization.front_matter
Open slide detail
02
other
Open slide detail
03
This is a standard IPO deal term sheet slide.plan_implementation
Open slide detail
04
The slide combines a funding timeline on the left with a strategic summary on the right.show_traction
Open slide detail
05
Uses a Venn diagram to illustrate the intersection of two critical clinical challenges.present_solution
Open slide detailBeat · Solution
06
Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's solution.frame_problem
Open slide detailBeat · Problem
07
Uses a visual comparison diagram to explain the mechanism of action and clinical benefit of selectivity.present_solution
Open slide detailBeat · Problem
08
The chart uses a Gantt-style visualization to show progress from discovery through IND enabling phases.plan_implementation
Open slide detail
09
Includes a section on 'Prior FDA Approval Experience' with company logos.other
Open slide detail
10
The slide features a 3D molecular rendering showing the inhibitor (pink) bound to the target protein (blue).present_solution
Open slide detail
11
The slide uses a three-part process flow to explain the biological mechanism of ROS1-driven disease and resistance.establish_context
Open slide detail
12
The table highlights the clinical limitations of current standard-of-care drugs (Crizotinib, Entrectinib) due to resistance mutations like G2032R and CNS involvsize_opportunity
Open slide detailBeat · Market Sizing
13
The table uses a green/white color coding to highlight the competitive advantage of NVL-520.compare_peers
Open slide detailBeat · Market Sizing
14
The slide uses a medical illustration to map specific TRK receptor inhibition (TRKB, TRKC, TRKA) to corresponding neurological and physiological side effects.frame_problem
Open slide detailBeat · Competition
15
The slide uses a structured table-like layout to define the product profile.present_solution
Open slide detail
16
Includes a table of IC50 values and a line chart showing tumor volume over time for different dosages.analyze_data
Open slide detail
17
Includes a heatmap table for IC50 values and two line charts showing tumor volume reduction in PDX models.present_solution
Open slide detail
18
The chart uses a logarithmic scale to show relative selectivity ratios.compare_peers
Open slide detail
19
The kinome tree is a standard visualization in pharmacology for kinase selectivity.present_solution
Open slide detail
20
The slide highlights CNS activity via brain penetration, a key component of the NVL-520 target product profile.present_solution
Open slide detail
21
The slide uses bioluminescence imaging to show tumor reduction and a Kaplan-Meier survival curve to show efficacy.show_traction
Open slide detail
22
The slide lists specific key opinion leaders (KOLs) and their respective institutions across the US, Spain, France, and the Netherlands.plan_implementation
Open slide detailLoop · Quick Win Big Bet
23
The slide uses a hybrid layout combining a staircase diagram for Phase 1 and a structured table for Phase 2.plan_implementation
Open slide detailLoop · Quick Win Big Bet
24
The slide uses a high-quality 3D molecular rendering to illustrate the mechanism of action.present_solution
Open slide detail
25
The slide uses a three-column process flow to explain the biological mechanism of ALK-driven cancer and resistance.establish_context
Open slide detail
26
The slide highlights the clinical unmet need as patients progress through lines of therapy, specifically noting resistance mutations and CNS involvement.size_opportunity
Open slide detailLoop · Cost Of Inaction
27
The table uses a green/white color coding to highlight the superior profile of NVL-655 compared to existing therapies.compare_peers
Open slide detailLoop · Cost Of Inaction
28
The slide uses a structured table format to define the product's key performance characteristics.present_solution
Open slide detail
29
The slide uses a color-coded heatmap to indicate potency (green for high potency, yellow for lower).analyze_data
Open slide detail
30
Includes a table of IC50 values and two line charts showing tumor volume reduction in CDX models.analyze_data
Open slide detail
31
The chart uses a logarithmic scale to show fold-selectivity. NVL-655 shows significantly higher selectivity for ALK variants compared to the other two drugs.compare_peers
Open slide detail
32
The slide uses a kinome tree diagram to visualize selectivity. The table defines the selectivity index based on IC50 ratios.present_solution
Open slide detail
33
Includes disclaimer regarding clinical studies and FDA feedback.analyze_data
Open slide detail
34
transition
Open slide detail
35
The slide uses a hexagonal process flow diagram to illustrate the three-step methodology.present_solution
Open slide detail
36
The slide uses a side-by-side comparison structure to highlight the target product profiles for ALK IXDN Resistance Mutations and HER2 Exon 20 Insertions.present_solution
Open slide detail
37
plan_implementation
Open slide detail
38
The slide uses a dual-track timeline: top for corporate events, bottom for clinical/R&D pipeline progress.show_traction
Open slide detail
39
The slide features a 3D molecular structure visualization, likely a protein-ligand complex.present_solution
Open slide detail
40
Features company logo and a molecular structure visualization.front_matter
Open slide detail